NFLX vs PFE: Which Is the Better Buy?
Side-by-side comparison of Netflix, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Netflix, Inc. · Communication Services
$77.38
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
NFLX has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NFLX |
PFE |
| Current Price |
$77.38 |
$25.22 |
| Fair Value Estimate |
$112.20 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$325.8B |
$143.7B |
| Forward P/E |
24.5x
|
19.2x
|
| EV / EBITDA |
9.7x
|
12.3x
|
| Price / Sales |
7.0x
|
2.3x
|
| Price / FCF |
27.4x
|
15.2x
|
| Revenue Growth YoY |
+16.2%
|
+5.4%
|
| Gross Margin |
49.0%
|
69.3%
|
| Operating Margin |
29.7%
|
23.4%
|
| Return on Equity |
49.2%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.65%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Netflix, Inc. operates a global streaming entertainment platform with a durable competitive moat driven by its massive scale, significant content investment, and advanced technology and data capabilities. The company benefits from strong revenue growth of 16.2% and earnings growth of 82.8% in the most recent quarter, supported by a subscriber base exceeding 300 million and expanding advertising r…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
NFLX |
PFE |
| Zone Low |
$84.15 |
$19.44 |
| Zone High |
$95.37 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|